On Friday, in the course of current trade, Shares of Alder Biopharmaceuticals Inc (NASDAQ:ALDR), dropped -2.89%, and is now trading at $42.35.
Alder BioPharmaceuticals, offered recent corporate highlights and stated its financial results for the second quarter ended June 30, 2015.
“We believe that ALD403 has the potential to transform migraine prevention and represents a very noteworthymarket opportunity due to its outstanding efficacy demonstrated in our proof-of-concept trial, delivering about one third of patients to 100% reduction in their migraines in any given month,” said Randall C. Schatzman, Ph.D., President and Chief Executive Officer of Alder. “ALD403 also has demonstrated a rapid onset and durable effect enabling the clinical development of two modes of infrequent administration, both infusion and self-administration, to allow chronic and high frequency migraine patients to select the treatment course that best suits their preferences and circumstances. We recently fortified our financial position through an equity offering that raised about $216.0 million of net proceeds, which leaves us in a strong position to work aggressively to move ALD403 towards the market and to advance ALD1613 and other promising preclinical product opportunities.”
Alder BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes various therapeutic antibodies in the United States and Australia.
During an Afternoon trade, Shares of Agios Pharmaceuticals Inc (NASDAQ:AGIO), dipped -3.74%, and is now trading at $96.27.
Agios Pharmaceuticals, stated business highlights and financial results for the second quarter ended June 30, 2015.
“In the first half of 2015, we continued to drive rapid and meaningful progress across our development programs, in addition to selecting our fourth molecule for development, AG-881, and advancing it into two Phase 1 studies,” said David Schenkein, M.D., chief executive officer of Agios. “Additionally, we recently initiated DRIVE PK, a Phase 2 study of AG-348 in PK deficiency patients, and are on track to initiate two global, registration-enabling Phase 3 studies of AG-221 and AG-120 in patients with acute myeloid leukemia in the next six to 12 months. These efforts bring us closer to our aim of being a late-stage biopharmaceutical company capable of changing the treatment paradigm for people with cancer and rare genetic disorders.”
Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism in the United States.
Shares of Gran Tierra Energy Inc. (NYSEMKT:GTE), during its Friday’s current trading session fell -3.56%, and is now trading at $2.17.
Gran Tierra Energy, declared its financial and operating results for the quarter ended June 30, 2015. All dollar amounts are in United States (“U.S.”) dollars unless otherwise indicated.
“In the second quarter, Gran Tierra designated a new administration team with noteworthyexperience and a proven track record of value creation. The new team has operational and technical experience across North America , Latin America , Asia , Europe , the Middle East and Africa ,” commented Gary Guidry , President and Chief Executive Officer of Gran Tierra. “Gran Tierra has a solid platform in Colombia with extensive exploration positions in proven onshore basins to support future growth of the company and we now have a more intensive planned focus on Colombia . During the quarter, the Company’s board approved a new capital program, focused on acceleration of development activities in Colombia . The Company is focusing on ensuring its cost structure is such that it remains competitive in all commodity price environments. The Company continues to have a robust balance sheet with zero debt and is in a strong financial position at a time of weak oil prices in contrast to many of our peers,” concluded Guidry.
Gran Tierra Energy Inc., an independent energy company, engages in the acquisition, exploration, development, and production of oil and gas properties in Colombia, Peru, and Brazil.
Finally, Edison International (NYSE:EIX), gained 0.79% Friday.
Edison International, stated second quarter 2015 net income on a GAAP basis of $379 million, or $1.16 per share, contrast to $536 million, or $1.64 per share, in the second quarter of 2014. On an adjusted basis, Edison International’s second quarter 2015 core earnings were $378 million, or $1.16 per share, contrast to $352 million, or $1.08 per share, in the second quarter of 2014.
“SCE remains focused on improving its safety and operational performance and continues to invest at high levels to support system reliability, public safety and California’s renewables mandates,” said Ted Craver, chairman and chief executive officer of Edison International. “Earnings improved in the second quarter primarily from federal tax benefits, but until SCE receives a decision in its 2015 General Rate Case, comparative results are not meaningful.”
Edison International, through its auxiliaries, generates and supplies electricity. The company generates electricity through hydroelectric, diesel, natural gas, nuclear, and photovoltaic sources.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
